# More durable, deeper PSA response in patients treated with Pluvicto plus standard of care (ARPI + ADT) vs. SoC alone.

*biotech · news · 2026-05-17 · The Manila Times*

## Key points

- Pluvicto combined with standard therapy reduces risk of PSA progression by 58% versus standard care alone.
- At 48 weeks, 87.4% of Pluvicto-treated patients achieved deep PSA reduction, vs 74.9% with standard care.
- Grade ≥3 adverse events occurred in 50.7% of Pluvicto combination patients, slightly higher than 43% on standard therapy.
- Regulatory submissions for Pluvicto in mHSPC have been filed in the US, China, and Japan, with decisions expected H2 2026.
- Pluvicto is the first radioligand therapy to show clinical benefit for PSMA+ mHSPC in a Phase III trial.

**Companies:** Novartis
**Countries:** United States, China, Japan, France, Germany, Italy, Spain, United Kingdom

[Read the full story on The Manila Times](https://www.manilatimes.net/2026/05/18/tmt-newswire/globenewswire/new-psmaddition-data-show-58-lower-risk-of-psa-progression-with-pluvicto-in-metastatic-hormone-sensitive-prostate-cancer/2345762)

---

Canonical: https://newsio.io/n/2514ca5d-2231-451d-99cf-a4df28df8a31/more-durable-deeper-psa-response-in-patients-treated-with-pluvicto-plus-standard
Summarized by Newsio from The Manila Times. https://newsio.io/how-it-works